Company overview
Basic information
Company name
Corda lines, UAB
Company code
306159076
VAT code
LT100015386917
Registered address
Kaunas, Europos pr. 122, LT-46351
Registration date
2022-10-11
Company age: 4 y.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Website
None
Indicators
Risk factors
Activity
Legal form
Private Limited Liability Company
NACE activity
Freight transport by road
Ownership form
Private without foreign capital
UAB "Corda lines"
Company code: 306159076
Address: Kaunas, Europos pr. 122, LT-46351
VAT code: LT100015386917
Description
This description was generated by artificial intelligence.
Corda lines, UAB (company code 306159076) is an operational private limited liability company registered on 2022-10-11. It is classified as a private company in the national private non-financial companies sector, under private ownership where Lithuanian natural and legal persons own more than 50% of the authorised capital and no foreign investor capital is present. Governance is described as CEO only, and the company is classified as micro. Its main activity is EVRK H.49.41.00, Freight transport by road. The company is based in Kaunas, Kauno m. sav., Kauno apskr., at Europos pr. 122, LT-46351. The share capital is €29.0K. Financially, the latest available annual results in the dataset are for 2024, when revenue was €56.8K, compared with €69.8K in 2023. The company reported a net loss of €74.4K in 2024, broadly in line with the €75.8K loss in 2023, while equity remained negative and liabilities increased to €192.9K. Staff data show an average of 4 employees so far in 2026, down from 5 in 2025, while the average monthly wage reached €1,070.15, up from €918.40 in 2025.
Download a detailed company report
Make confident decisions with all the information about Corda lines, UAB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.